PRACTICE GROUP ANALYSIS
LIFE CYCLE FIRMS
Practice Group Overview Goodwin Procter
The finance and transactional team at the firm is “a premiere corporate group” according to one practitioner. Leading the group is partner Mitchell Bloom who handles both the day-today corporate work of small start-ups to complex licensing deals. Bloom shares a distinguished practice with Kingsley Taft and Lawrence Wittenberg, all of whom are extremely versatile and can handle the “A-Z” of finance and transactional deals in the industry. The corporate group at Goodwin is buttressed by a top-flight patent team, which is one of the largest in the market focused on life sciences, and provides the corporate team with a steadfast resource to prepare a patent portfolio for commercialization. “They have incredible depth and technical skills on their IP bench and are among the best practices in the industry,” raves one colleague. Edmund “Ted” Pitcher is a leading figure in the patent strategy and management field and has been advising industry clients for over three decades. Pitcher has represented clients in an array of industries including diagnostics, DNA sequencing, and protein therapeutics to name a few. Goodwin excels in patent litigation for life sciences clients in both general and Hatch-Waxman proceedings. Partner David Hashmall has done some of the industry’s finest work on behalf of generic drug manufacturers in Hatch-Waxman litigation. The firm also represents branded manufacturers in ANDA litigation and partner Frederick Rein has taken the lead in many of these cases. “Their patent ligation team can do it all and being able to comfortably deal with any type of ANDA litigation is attractive for large pharmaceutical clients,” explains one competitor. Despite having a smaller regulatory function at the firm, peers have noticed that the firm has taken on more regulatory work recently, a perfect complement to the firm’s traditional strengths in the IP and transactional spaces. “One area they have become much more active in is working on regulatory matters, which is a nice addition to their current strength,” states one peer. Mark Heller chairs the FDA group and brings years of experience working with government agencies to the burgeoning practice. He spent time working for both the FTC and the FDA before joining Goodwin, spending nearly two decades on the legislative side of the business before coming to the firm in 2007. Clients marvel at their experience working with the life sciences industry group at Goodwin. “They were able to handle all of our needs, and their attorneys were so knowledgeable about the industry,” boasts one client. “We were really impressed with the service they provided for us.”
LIFE SCIENCES STARS
REGULATORY Mark A Heller, Washington, DC INTELLECTUAL PROPERTY Kevin J Culligan, New York Marta E Delsignore, New York Duncan A Greenhalgh, New York Marta E Gross, New York David M Hashmall, New York David E Kleinfeld, San Diego Francis C Lynch, Boston Edmund “Ted” Pitcher, Boston Frederick H Rein, New York Daryl L Wiesen, Boston FINANCE & TRANSACTIONAL Mitchell S Bloom, Boston Kingsley L Taft, Boston Lawrence S Wittenberg, Boston NON-IP LITIGAT %=8?9?9=I
59P?)??????4? ??9??e??()AI
Q%
? I=U@? I-=]8?=?1%?M
%9
?MQIL()15 ?1%?M
%9
L?????((???((0